Topiramate Tablet
Product Images NDC 70518-0625

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70518-0625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Topiramate 25mg 70518 0625 00

Topiramate 25 mg oral tablets quantity 30 label by RemedyRepack Inc. The label shows the proprietary name Topiramate, strength 25 mg, dosage form tablet, and quantity of 30 tablets. It includes an NDC number 70518-0625-00 and the manufacturer Cipla USA, Inc. with instructions to keep out of reach of children. Storage temperature and repackaging details are also provided.*

FDA Label Image

Topiramate 25mg 70518 0625 01

Topiramate 25 mg tablet label by RemedyRepack Inc. The label indicates the product is oral tablets with a quantity of 30. It includes a barcode, NDC 70518-0625-01, and manufacturing details by Cipla USA, Inc. with location Miami, FL. It has storage instructions and a note to see package insert for directions.*

FDA Label Image

Topiramate 25mg 70518 0625 02

Topiramate 25 mg oral tablet, single unit quantity, repackaged by RemedyRepack Inc. Label includes NDC 70518-0625-02, manufacturer Cipla USA, and directions to see package insert. Storage instructions and caution to keep out of reach of children are also visible.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

Chemical structure of topiramate showing its molecular framework with distinct functional groups, including multiple oxygen atoms and sulfonamide moieties, in a ring and branching arrangement.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

A line graph showing cumulative rates for time to first seizure over a period of 500 days for two dosages of Topiramate: 50 mg/day and 400 mg/day. The x-axis represents time in days and the y-axis shows cumulative rates. The graph compares seizure occurrence rates between the two dosage groups with statistical significance noted (p = 0.0002).*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

A bar chart comparing the change from baseline to double-blind phase in average weekly migraine period days (± SEM) across placebo and various Topamax (topiramate) doses (50 mg/day, 100 mg/day, 200 mg/day). Data is shown for two studies (Study 10 and Study 11) with bars representing each study’s results at each dose level.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.